#United States #Caris Life Sciences #Irving #Breast Cancer #Precision Medicine

Caris Life Sciences to Present Groundbreaking Research at SABCS 2024

Caris Life Sciences, renowned for its advancements in precision medicine, will present pivotal research findings at the 2024 San Antonio Breast Cancer Symposium (SABCS) scheduled from December 10-13. Collaborating with prominent cancer centers, Caris will showcase seven studies covering various breast cancer types, notably focusing on male breast cancer, which is frequently overlooked. The presentations highlight the extensive capabilities of Caris' multimodal database in providing new insights that could significantly impact patient care through enhanced diagnosis, treatment strategies, and therapeutic responses.

Commitment to Precision Oncology

Dr. George W. Sledge, Jr., Executive Vice President and Chief Medical Officer of Caris, emphasized that the research underscores Caris' commitment to data-driven molecular innovation. The emphasis on male breast cancer represents an important step in rectifying this often-ignored diagnosis. The research findings demonstrate the unique role of comprehensive molecular profiling in understanding and addressing various tumor types, including rare cancers. Additionally, President David Spetzler highlighted the firm's real-world evidence from over 748,000 cases, integrating molecular data with clinical outcomes, thereby paving the road for personalized therapies and better patient access to treatment options.

Spotlight Presentation Highlights

1. Metaplastic Triple Negative Breast Cancer Study

One of the spotlight presentations, "Molecular and Immune Landscape of Metaplastic Triple Negative Breast Cancer Compared with Invasive Ductal Triple Negative Breast Cancer," will take place on December 12. This study, conducted with several members of the Caris Precision Oncology Alliance, revealed that Metaplastic Triple Negative Breast Cancer (M-TNBC) possesses distinct molecular and immune features, indicating its aggressive nature compared to its invasive ductal counterpart. These findings are pivotal for developing tailored therapeutic strategies for patients suffering from this rare and significant form of breast cancer.

2. Mechanisms of Resistance Study

Another significant study titled, "Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multi-omic Molecular Profiling," will be presented by Dr. Sledge on December 13. Analyzing over 2,000 samples treated with Trastuzumab Deruxtecan (T-DXd), the multi-omic approach explained mechanisms of resistance to the drug, providing oncologists with essential insights to personalize treatment plans effectively.

Further Research Presentations

Additional studies will focus on various molecular profiles and immune responses in male breast cancer, spliceosome mutations in metastatic cases, and the prognostic relevance of oncogenetic pathway alterations. These presentations not only highlight Caris' commitment to precision oncology but also the importance of understanding sex-specific differences in breast cancer biology.

The Caris Precision Oncology Alliance

The Caris Precision Oncology Alliance, consisting of 96 leading cancer research institutions, including 47 NCI-designated centers, collaborates to enhance precision oncology and refine standards of care through biomarker-driven studies. Such collaborative efforts are crucial in advancing the understanding and application of personalized medicine in cancer care.

About Caris Life Sciences

Founded to harness the potential of precision medicine, Caris Life Sciences continuously strives to revolutionize healthcare through innovative solutions. Their comprehensive molecular profiling services utilize advanced AI-driven technologies to analyze the complexities of various diseases. With a solid infrastructure supporting global operations, Caris aims to improve patient outcomes through tailored therapeutic options and ongoing research efforts. For more information, visit CarisLifeSciences.com.